Patents Examined by Kevin K. Hill
-
Patent number: 11958887Abstract: The invention provides compositions and methods for treating tuberous sclerosis complex (TSC). In particular, provided are condensed tuberins (cTuberins), cTuberin nucleic acids, and recombinant adeno-associated viruses (rAAVs) carrying a cTuberin nucleic acid for treating a patient with TSC.Type: GrantFiled: May 17, 2018Date of Patent: April 16, 2024Assignee: The General Hospital CorporationInventors: Xandra Breakefield, Casey Maguire, Shilpa Prabhakar, David Yellen
-
Patent number: 11938197Abstract: Polynucleotides and vectors can be used for the expression of a transgene in cells, such as liver cells. The expression of the transgene from the polynucleotides and vectors can be useful in gene therapy. Various methods can be used for expressing the transgene from the polynucleotides and vectors in liver cells.Type: GrantFiled: January 10, 2018Date of Patent: March 26, 2024Assignees: THE SYDNEY CHILDREN'S HOSPITALS NETWORK (RANDWICK AND WESTMEAD (INCORPORATING THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN), CHILDREN'S MEDICAL RESEARCH INSTITUTEInventors: Ian Alexander, Sharon Cunningham
-
Patent number: 11910787Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.Type: GrantFiled: November 17, 2020Date of Patent: February 27, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
-
Patent number: 11873505Abstract: The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for increasing production of a TLR3 precursor protein. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the subject's immune system is, or is likely to become, dysregulated and where the production of the TLR3 precursor protein may result in an increased production of a functional and bioavailable TLR3 protein product, which may be of therapeutic benefit.Type: GrantFiled: December 23, 2020Date of Patent: January 16, 2024Assignee: Wyvern Pharmaceuticals Inc.Inventor: Bradley G. Thompson
-
Patent number: 11858969Abstract: Disclosed herein are engineered light-sensitive proteins, for example channelrhodopsins and variants thereof. Also disclosed are compositions for expressing the light-sensitive proteins in cells, tissues, organs and subjects, and methods for using the light-sensitive proteins to, for example, enable minimally-invasive neuronal circuit interrogation in living organism, and treat neuronal and ocular disorders.Type: GrantFiled: September 17, 2019Date of Patent: January 2, 2024Assignee: California Institute of TechnologyInventors: Viviana Gradinaru, Claire N. Bedbrook, Frances H. Arnold, Kevin K. Yang
-
Patent number: 11851659Abstract: The present disclosure is directed to genome editing systems, reagents and methods for immunooncology.Type: GrantFiled: March 21, 2018Date of Patent: December 26, 2023Assignees: Novartis AG, Intellia Therapeutics, Inc.Inventors: Jennifer Brogdon, Ming-Wei Chen, Hyungwook Lim, Yi Yang, Morag Stewart, Sarah Hesse
-
Patent number: 11845965Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.Type: GrantFiled: January 9, 2020Date of Patent: December 19, 2023Assignee: Sangamo Therapeutics, Inc.Inventors: Jeffrey C. Miller, Edward J. Rebar
-
Patent number: 11827898Abstract: Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.Type: GrantFiled: June 14, 2018Date of Patent: November 28, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Jean Bennett, Junwei Sun, Jeannette Bennicelli
-
Patent number: 11802277Abstract: Thermostable Cas9 nucleases. The present invention relates to the field of genetic engineering and more particularly to nucleic acid editing and genome modification. The present invention provides in isolated Cas protein or polypeptide fragment thereof having an amino acid sequence of SEQ ID NO: 1 or a sequence of at least 77% identity therewith, wherein the Cas protein or polypeptide is capable of DNA cleavage at a temperature in the range 50° C. and 100° C. inclusive. The invention further provides isolated nucleic acid molecules encoding said Cas9 nucleases, expression vectors and host cells. The Cas9 nucleases disclosed herein provide novel tools for genetic engineering at elevated temperatures and are of particular value in the genetic manipulation of thermophilic organisms; particularly microorganisms.Type: GrantFiled: June 19, 2020Date of Patent: October 31, 2023Assignee: Wageningen UniversiteitInventors: John Van Der Oost, Martinus Johannes Arnoldus Daas, Servatius Wilhelmus Maria Kengen, Willem Meindert De Vos
-
Patent number: 11771747Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences having multiple iterations of KRAS neoepitope-encoding sequences and/or lacking immunodominant epitopes. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines.Type: GrantFiled: April 22, 2022Date of Patent: October 3, 2023Assignee: Gritstone Bio, Inc.Inventors: Karin Jooss, Roman Yelensky, James Xin Sun, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer, Monica Lane
-
Patent number: 11732246Abstract: Viral vectors comprising engineered hOTC DNA and RNA sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hOTC for treatment of liver fibrosis and/or cirrhosis in OTCD patients by administering hOTC.Type: GrantFiled: August 17, 2020Date of Patent: August 22, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Lili Wang, James M. Wilson
-
Patent number: 11685925Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.Type: GrantFiled: September 8, 2016Date of Patent: June 27, 2023Assignee: Synlogic Operating Company, Inc.Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
-
Patent number: 11666665Abstract: Methods of editing target nucleic acids are provided using a guide RNA and a Cas9 protein to excise exons in a target gene and where the edited gene is expressed to produce a truncated polypeptide.Type: GrantFiled: March 30, 2020Date of Patent: June 6, 2023Assignee: President and Fellows of Harvard CollegeInventors: Amy J. Wagers, Mohammadsharif Tabebordbar, Wei Leong Chew, George M. Church
-
Patent number: 11661581Abstract: Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.Type: GrantFiled: May 24, 2018Date of Patent: May 30, 2023Assignee: University of MassachusettsInventors: Merav Socolovsky, Ralph Scully, Yung Hwang
-
Patent number: 11629340Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.Type: GrantFiled: September 2, 2019Date of Patent: April 18, 2023Assignee: OBSIDIAN THERAPEUTICS, INC.Inventors: Vipin Suri, Dan Jun Li, Dexue Sun, Byron Delabarre, Vijaya Balakrishnan, Brian Dolinski, Mara Christine Inniss, Grace Y. Olinger
-
Patent number: 11617801Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: GrantFiled: April 21, 2020Date of Patent: April 4, 2023Assignee: The United States of America,as represented by the Secretary, Department of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suja Hiriyanna, Tiansen Li
-
Patent number: 11608510Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and/or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.Type: GrantFiled: March 29, 2019Date of Patent: March 21, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Katja Pekrun, Mark A. Kay
-
Patent number: 11603519Abstract: Provided is a T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24. A T cell receptor capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 28 or a complex of the peptide and HLA-A02. Disclosed T cell receptors are useful in treating or avoiding cancers which are associated with expression of glypican-3.Type: GrantFiled: February 5, 2018Date of Patent: March 14, 2023Assignees: National Cancer Center Japan, Kyoto University, Takeda Pharmaceutical Company LimitedInventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
-
Patent number: 11578341Abstract: A rAAV vector is described herein which has an AAVhu68 capsid and at least one expression cassette in the capsid. The at least one expression cassette comprises nucleic acid sequences encoding a functional SMN protein and expression control sequences that direct expression of the SMN sequences in a host cell. Also provided are compositions containing this rAAVhu68.SMN vector and methods of using same for spinal muscular atrophy in a patient.Type: GrantFiled: February 27, 2018Date of Patent: February 14, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Christian Hinderer, Nathan Katz, Qiang Wang
-
Patent number: 11564996Abstract: Compositions and methods are provided for treating Leber congenital amaurosis (LCA) in a subject. In one aspect, a recombinant adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding Lebercilin. In another aspect, Lebercilin has an amino acid sequence of SEQ ID NO: 1. In yet another aspect, the nucleic acid molecule has a sequence of SEQ ID NO: 3 or a variant thereof. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.Type: GrantFiled: March 1, 2018Date of Patent: January 31, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Jean Bennett, Jeannette Bennicelli, Junwei Sun, Ji Yun Song, Sergei Nikonov